The therapeutic effect was more evident, with complete tumor regression, when the anti-CTLA-4 agent was associated with inhibitors of OX40 (TNF receptor mainly expressed on T lymphocytes), efficaciously reducing Tregs inside the tumor and increasing the activation and proliferation of CD8+ TILs [17]. Here, TNFRSF4 is linked to neoplasm.